— Know what they know.
Not Investment Advice
Also trades as: DCAL.NS (NSE) · $vol 1M

DCAL.BO BSE

Dishman Carbogen Amcis Limited
1W: -10.5% 1M: -16.8% 3M: -23.3% YTD: -28.2% 1Y: -40.9% 3Y: -2.1% 5Y: -23.1%
₹151.20 ($1.57)
+0.45 (+0.30%)
 
BSE · Healthcare · Biotechnology · Tech Score Sell · Power 36 · ₹23.6B mcap · 55M float · 0.040% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market Cap₹23.6B ($245.2M)
52W Range129-306.75
Volume12,819
Avg Volume21,778
Beta0.61
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOArpit Janmejay Vyas
Employees934
SectorHealthcare
IndustryBiotechnology
IPO Date2017-09-21
Websiteimdcal.com
Dishman Corporate House
Ahmedabad, GU 380058
IN
91 27 1742 0102
About Dishman Carbogen Amcis Limited

Established in 1983 and headquartered in Ahmedabad, India, Dishman Carbogen Amcis Limited delivers contract research and manufacturing solutions to the global and Indian pharmaceutical sectors. The company's activities are structured across two principal segments: Contract Research and Manufacturing Services, and Marketable Molecules. Its comprehensive product range encompasses the production and distribution of bulk drugs, active pharmaceutical ingredients (APIs), including both generic and highly potent varieties. Furthermore, it supplies specialized chemical compounds such as phase transfer catalysts, quaternary ammonium compounds, phosphoranes, and Wittig reagents, alongside a variety of vitamin D products and their analogues, cholesterol, lanolin-derived products, and other fine chemicals. Dishman Carbogen Amcis also offers consumer-oriented items like hand and body wash, sanitizers, antiseptics, and various disinfectant formulations, in addition to diverse pharmaceutical and cosmetic goods. Dishman Carbogen Amcis Limited functions as a subsidiary of Adimans Technologies LLP.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms